Wungki Park, MD MS (@centralparkwmd) 's Twitter Profile
Wungki Park, MD MS

@centralparkwmd

🗽@MSKCancerCenter 🩺 #GI #oncologist 💜#PancreaticCancer 💚#BiliaryCancer 🧬 #science #fan 🏃🏻‍♂️26.2 #runner early 💊#drug #development #trialist #췌장암 #담도암

ID: 343223445

linkhttps://scholar.google.com/citations?user=Hoe4SIAAAAAJ&hl=en calendar_today27-07-2011 07:16:03

5,5K Tweet

2,2K Followers

984 Following

Brandon Huffman, MD (@bhuffmanmd) 's Twitter Profile Photo

Results of randomized phase II #PDAC trial that will be a benchmark for future trials. Patients receiving 2nd-line gemcitabine/nab-paclitaxel alone after FOLFIRINOX had median OS of 6.6 months, the median PFS was 2.7 months, and the ORR was 2.9%. ⬇️⬇️⬇️ jamanetwork.com/journals/jaman…

Results of randomized phase II #PDAC trial that will be a benchmark for future trials. Patients receiving 2nd-line gemcitabine/nab-paclitaxel alone after FOLFIRINOX had median OS of 6.6 months, the median PFS was 2.7 months, and the ORR was 2.9%.

⬇️⬇️⬇️
jamanetwork.com/journals/jaman…
Anirban Maitra (@aiims1742) 's Twitter Profile Photo

From MD Anderson Cancer Center team: A clinical series of an uncommon, late and unfortunately aggressive complication of #PancreaticCancer: Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma academic.oup.com/oncolo/advance…

OncoAlert (@oncoalert) 's Twitter Profile Photo

The #OncoAlert5k 🚨 at #ESMO24 Barcelona🇪🇸 REGISTRATION NOW OPEN oncoalert.m-pages.com/8e4BL2/the-onc… WE ARE ALMOST AT CAPACITY REGISTRATIONS WILL CLOSE SOON!! Warm invitation to join the OncoAlert Network and friends to this 5k in Barcelona on Saturday September 14, 2024 at 7am. The

Myriam Chalabi (@myriamchalabi) 's Twitter Profile Photo

Abstract titles for #ESMO24 now online! Full NICHE-3 cohort (59 pts with dMMR colon cancer treated with neoadj nivo/rela) will be presented in proferred paper session + more neoadj IO from Imhotep, and wonderful Jenny Seligmann as discussant. Stay tuned for more exciting💥💥💥news!

Abstract titles for #ESMO24 now online! Full NICHE-3 cohort (59 pts with dMMR colon cancer treated with neoadj nivo/rela) will be presented in proferred paper session + more neoadj IO from Imhotep, and wonderful <a href="/JenSeligmann/">Jenny Seligmann</a> as discussant. Stay tuned for more exciting💥💥💥news!
Sandra P D'Angelo, MD (@sandrapdangelo) 's Twitter Profile Photo

Afamicel, TCR targeting MAGEA-4 approved for #synovial sarcoma. A remarkable advancement for our patients, laying the foundation for future efforts in solid tumors. businesswire.com/news/home/2024…

Kohei shitara (@koheishitara) 's Twitter Profile Photo

Pleased to share our experience of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma ESMO - Eur. Oncology Gastrointestinal Oncology. 97.5% success rate using biopsy samples with median turn around time of 7 days. esmogastro.org/article/S2949-…

Pleased to share our experience of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma <a href="/myESMO/">ESMO - Eur. Oncology</a>  Gastrointestinal Oncology. 97.5% success rate using biopsy samples with median turn around time of 7 days. esmogastro.org/article/S2949-…
Chris Iacobuzio (@ciacobu) 's Twitter Profile Photo

Excited to get this story out by my incredibly talented graduate student Haochen Zhang for his thesis work. Keep an eye out for him, rising star for sure! Genomic evolution of pancreatic cancer at single-cell resolution biorxiv.org/content/10.110…

Haochen Zhang (@haochenz39) 's Twitter Profile Photo

It is a great honor to graduate from Chris Iacobuzio’s lab at GSK Graduate School this summer and preprint my PhD work. Honored to take on the challenge of pancreatic cancer research. Everyone stayed tuned for Chris’ lab because we have many great works brewing ♨️ biorxiv.org/content/10.110…

It is a great honor to graduate from <a href="/ciacobu/">Chris Iacobuzio</a>’s lab at <a href="/GSKGradSchool/">GSK Graduate School</a> this summer and preprint my PhD work. Honored to take on the challenge of pancreatic cancer research. Everyone stayed tuned for Chris’ lab because we have many great works brewing ♨️

biorxiv.org/content/10.110…
Benoit JC Rousseau (@benjcrousseau) 's Twitter Profile Photo

Check out our News and View article Nature Medicine where we discuss neoadjuvant immunotherapy/organ preservation for MMRd colorectal cancers! What are local immunological outcomes for early resection and organ-sparing strategies? Andrea Cercek Luis Diaz doi.org/10.1038/s41591…

Fresia Pareja (@fresiapareja) 's Twitter Profile Photo

Thank you Cancer Research for highlighting our work. This collaboration between Memorial Sloan Kettering Cancer Center and Paige showcases how integrating AI and genomics can help discover novel biology. Truly grateful to Jorge Reis-Filho, Thomas J. Fuchs David Klimstra and all the amazing contributors

Eytan Ruppin, MD, PhD (@ncieytanruppin) 's Twitter Profile Photo

Happy to share a collaborative study led by Jinghui Zhang and Sara Federico St. Jude Research in NEJM! First successful treatment of pediatric high-risk refractory neuroblastoma with a PARP inhibitor 👇 nejm.org/doi/full/10.10…

Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer Journal of Clinical Oncology doi.org/10.1200/JCO.23… 🔎CALGB/SWOG 80702 (Alliance) 👉improved DFS & OS in tumors w/ PIK3CA mutations ❓ready of implementation in clinical practice ESMO - Eur. Oncology

Improved Survival With Adjuvant Cyclooxygenase 2
Inhibition in PIK3CA-Activated Stage III Colon Cancer
<a href="/JCO_ASCO/">Journal of Clinical Oncology</a> 
doi.org/10.1200/JCO.23…
🔎CALGB/SWOG 80702 (Alliance)
👉improved DFS &amp; OS in tumors w/ PIK3CA mutations   
❓ready of implementation in clinical practice
<a href="/myESMO/">ESMO - Eur. Oncology</a>